Belite Bio (BLTE) Profit After Tax (2022 - 2026)
Belite Bio (BLTE) posted quarterly Profit After Tax of -$26.9 million for Q1 2026, down 88.68% year-over-year from -$238.0 million in Q1 2025, and up 99.89% quarter-over-quarter from -$25.3 billion in Q4 2025.
Analysis
Belite Bio (BLTE) Profit After Tax (2022 - 2026) Analysis & Trends
Belite Bio's Profit After Tax history runs 5 years deep, the most recent figure standing at -$26.9 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 88.68% year-over-year to -$26.9 million; the TTM figure through Mar 2026 stood at -$63.4 billion (down 123.99% YoY), while the FY2025 annual figure was -$77.5 million, down 112.7% from the prior year.
- Profit After Tax for Q1 2026 stood at -$26.9 million, up from -$25.3 billion in the prior quarter.
- The five-year high for Profit After Tax was -$6.8 million in Q4 2022, with the low at -$25.3 billion in Q4 2025.
- The 5-year median for Profit After Tax is -$6.9 billion (2023), against an average of -$7.4 billion.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax plunged 144371.46% in 2024, then soared 99.82% in 2025.
- Belite Bio's Profit After Tax stood at -$6.8 million in 2022, then retreated by 3.07% to -$7.0 million in 2023, then slumped by 144371.46% to -$10.1 billion in 2024, then plunged by 150.73% to -$25.3 billion in 2025, then soared by 99.89% to -$26.9 million in 2026.
- Business Quant data shows BLTE's Profit After Tax at -$26.9 million in Q1 2026, -$25.3 billion in Q4 2025, and -$21.7 billion in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Belite Bio | 6.28 Bn | 6.28 Bn | - | -28.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -28.41 Mn |
| Mar 31, 2026 | -26.94 Mn |
| Dec 31, 2025 | -253.24 |
| Sep 30, 2025 | -21.69 Mn |
| Jun 30, 2025 | -16.32 Mn |
| Mar 31, 2025 | -14.28 Mn |
| Dec 31, 2024 | -101.00 |
| Sep 30, 2024 | -8.68 Mn |
| Jun 30, 2024 | -9.49 Mn |
| Mar 31, 2024 | -7.87 Mn |
| Dec 31, 2023 | -6.99 Mn |
| Sep 30, 2023 | -10.94 Mn |
| Jun 30, 2023 | -68.12 |
| Mar 31, 2023 | -6.90 Mn |
| Dec 31, 2022 | -6.78 Mn |
| Jun 30, 2022 | -2.39 Mn |